Seeing the Signs: Multidisciplinary Strategies to Manage Ocular Toxicities Associated With Cancer Therapies

Release Date: November 26, 2025

Expiration Date: November 26, 2026

Activity Overview

In the rapidly expanding oncology treatment landscape, multidisciplinary care is essential for managing any treatment-related adverse events. This program will provide eye care clinicians with the knowledge and competence to manage ocular toxicities associated with antibody-drug conjugates, monoclonal antibodies, and selective estrogen receptor degraders to optimize patient outcomes. It is an archived webcast of a live program presented on October 18, 2025.

Target Audience

This educational activity is directed toward ophthalmologists, optometrists, medical oncologists, advanced practice providers, nurses, and other health care providers involved in the management of patients with cancer who are at risk of ocular adverse events due to their treatment regimen.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Describe the mechanisms of emerging targeted cancer therapies that can lead to ocular toxicities.
• Apply evidence-based strategies for the early identification, monitoring, and management of ocular adverse events in patients with cancer treated with targeted therapies.
• Apply multidisciplinary strategies to optimize coordinated care between oncology and eye care specialists in managing ocular toxicities.
• Integrate shared decision-making to promote patient awareness, engagement, and timely reporting of ocular symptoms.